Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Share-based Compensation (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Share-based Compensation for 14 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 1.01% year-over-year to $3.9 million, compared with a TTM value of $14.0 million through Dec 2025, down 23.75%, and an annual FY2025 reading of $14.0 million, down 23.75% over the prior year.
  • Share-based Compensation was $3.9 million for Q4 2025 at Karyopharm Therapeutics, up from $2.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $15.1 million in Q2 2022 and bottomed at $2.8 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $6.0 million, with a median of $5.4 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 85.53% in 2022, then crashed 59.85% in 2023.
  • Year by year, Share-based Compensation stood at $6.9 million in 2021, then decreased by 10.13% to $6.2 million in 2022, then decreased by 16.05% to $5.2 million in 2023, then fell by 25.43% to $3.9 million in 2024, then grew by 1.01% to $3.9 million in 2025.
  • Business Quant data shows Share-based Compensation for KPTI at $3.9 million in Q4 2025, $2.8 million in Q3 2025, and $3.6 million in Q2 2025.